[go: up one dir, main page]

WO2006010568A3 - Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung - Google Patents

Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung Download PDF

Info

Publication number
WO2006010568A3
WO2006010568A3 PCT/EP2005/008031 EP2005008031W WO2006010568A3 WO 2006010568 A3 WO2006010568 A3 WO 2006010568A3 EP 2005008031 W EP2005008031 W EP 2005008031W WO 2006010568 A3 WO2006010568 A3 WO 2006010568A3
Authority
WO
WIPO (PCT)
Prior art keywords
diones
pyrimidine
pyrido
ones
furo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/008031
Other languages
English (en)
French (fr)
Other versions
WO2006010568A2 (de
Inventor
Claudia Reichelt
Alexander Ludwig
Alexander Schulze
Mohammed Daghish
Siegfried Leistner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curacyte Discovery GmbH
Original Assignee
Curacyte Discovery GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04017543A external-priority patent/EP1619197A1/de
Priority claimed from DE102005013622A external-priority patent/DE102005013622A1/de
Application filed by Curacyte Discovery GmbH filed Critical Curacyte Discovery GmbH
Publication of WO2006010568A2 publication Critical patent/WO2006010568A2/de
Publication of WO2006010568A3 publication Critical patent/WO2006010568A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft neue Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 H,3H)-dione und -4(3H)-one (X=C-H, Y=S), Thieno[2,3-d:4,5-d']dipyrimidin-2,4(1 H,3H)-dione und -4(3H)-one (X=N, Y=S) sowie Pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2,4(1 H,3H)-dione und -4(3H)-one (X=C-H, Y=0) und Furo[2,3-d:4,5-d']dipyrimidin-2,4(1 H,3H)-dione und -4(3H)-one (X=N, Y=O) der allgemeinen Formeln 1 a und 1 b, Verfahren zu deren Herstellung, pharmazeutische Zubereitungen, die diese Verbindungen und/oder deren Tautomere und daraus herstelibare physiologisch verträgliche Salze und/oder deren Solvate enthalten, sowie die pharmazeutische Verwendung dieser Verbindungen, deren Tautomere, Salze oder Solvate, als Inhibitoren der TNFα-Freisetzung.
PCT/EP2005/008031 2004-07-23 2005-07-22 Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung Ceased WO2006010568A2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04017543A EP1619197A1 (de) 2004-07-23 2004-07-23 Substituierte Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1H,3H)dione und -4(3H)one sowie Pyrido[3',2':4,5]furo[3,2-d]-pyrimidin-2,4(1H,3H)dione und -4(3H)one zur Verwendung als Inhibitoren der TNF-alpha Freisetzung
EP04017543.2 2004-07-23
DE102005013622A DE102005013622A1 (de) 2005-03-24 2005-03-24 Synthese substituierter Thieno[2,3-d:4,5-d']dipyrimidin-2,4(1H,3H)-dione und -4(3H)-one als TNFα-Freisetzungshemmer
DE102005013622.2 2005-03-24

Publications (2)

Publication Number Publication Date
WO2006010568A2 WO2006010568A2 (de) 2006-02-02
WO2006010568A3 true WO2006010568A3 (de) 2006-09-14

Family

ID=35385316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/008031 Ceased WO2006010568A2 (de) 2004-07-23 2005-07-22 Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung

Country Status (1)

Country Link
WO (1) WO2006010568A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005013621A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
AU2007207536A1 (en) * 2006-01-17 2007-07-26 Signal Pharmaceuticals, Llc Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
EP3048106B1 (de) 2011-11-23 2019-11-06 Cancer Research Technology Limited Thienopyrimidinverbindungen als inhibitoren von atypischer proteinkinase c
WO2016022295A1 (en) 2014-08-06 2016-02-11 Valencell, Inc. Optical physiological sensor modules with reduced signal noise

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1277738A1 (de) * 2000-04-27 2003-01-22 Yamanouchi Pharmaceutical Co. Ltd. Kondensierte heteroarylderivate
EP1323719A1 (de) * 1999-03-30 2003-07-02 Nippon Soda Co., Ltd. Thienopyrimidin-Verbindungen und Verfahren zu ihrer Herstellung
US20040009978A1 (en) * 2000-04-27 2004-01-15 Masahiko Hayakawa Fused heteroaryl derivatives
WO2005076861A2 (en) * 2004-02-04 2005-08-25 University Of Virginia Patent Foundation Compounds that inhibit hiv particle formation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323719A1 (de) * 1999-03-30 2003-07-02 Nippon Soda Co., Ltd. Thienopyrimidin-Verbindungen und Verfahren zu ihrer Herstellung
EP1277738A1 (de) * 2000-04-27 2003-01-22 Yamanouchi Pharmaceutical Co. Ltd. Kondensierte heteroarylderivate
US20040009978A1 (en) * 2000-04-27 2004-01-15 Masahiko Hayakawa Fused heteroaryl derivatives
WO2005076861A2 (en) * 2004-02-04 2005-08-25 University Of Virginia Patent Foundation Compounds that inhibit hiv particle formation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A.M. SHESTOPALOV ET AL.: "One-pot synthesis of 4,6-diaryl-3-cyanopyridine-2(1H)-thiones and their transformation to substituted thieno[2,3-b;4,5-b]dipyridines and pyrido[3',2':4,5]thieno[3,2-d]pyrimidines13", RUSSIAN CHEM. BULL., vol. 52, no. 10, 2003, pages 2203 - 2206, XP002310688 *
ARTEMOV, V. A. ET AL: "Regioselective synthesis of substituted thieno(selenopheno)[2,3- b]pyridines and pyrido[3',2':4,5]thieno(selenopheno)[3,2- d]pyrimidines based on 3-cyanopyridine-2(1H)-thiones, -selenones and N-cyanochloroacetamidine", KHIMIYA GETEROTSIKLICHESKIKH SOEDINENII , (1), 122-32 CODEN: KGSSAQ; ISSN: 0132-6244, 1994, XP008040258 *
BAKHITE, ETIFY A. ET AL: "Synthesis and antimicrobial activity of some new pyrido[3',2':4,5]thieno[3,2-d]pyrimidine derivatives", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS , 179(3), 513-520 CODEN: PSSLEC; ISSN: 1042-6507, 1 March 2004 (2004-03-01), XP008056401 *
CLARK, JIM ET AL: "Heterocyclic studies. Part 43. Thieno[2,3-d:4,5-d']dipyrimidines", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY (1972-1999) , (9), 2005-8 CODEN: JCPRB4; ISSN: 0300-922X, 1984, XP002356592 *
EL-NEAIRY, MOHAMED A. A.: "Utility of cyanothioacetamide and its derivatives in heterocyclic synthesis: synthesis and characterization of several new pyridine, pyrazolo[3,4-b]pyridine, thieno[2,3-b]pyridine and pyrido[5,4-b]thieno[3',2'-d']pyrimidine derivatives", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS , 148, 189-200 CODEN: PSSLEC; ISSN: 1042-6507, 1999, XP008049446 *
G. WAGNER AND N. BÖHM: "Synthese von 3-alkyl-2-amno-pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-onen aus 3-Ethoxycarbonylamino-thieno[2,3-b]pyridin-2-carbonsäureethylestern und -2-carbonsäureamiden", PHARMAZIE, vol. 48, 1993, pages 95 - 99, XP002310689 *
ROSHANI, M. ET AL.: "A convenient synthesis of new pyridothienopyrimidin-4 (3H) ones and pyridothienopyrimidin-2 4(1Hm 3H) diones", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, vol. 179, no. 6, June 2004 (2004-06-01), pages 1153 - 1157, XP008040303 *

Also Published As

Publication number Publication date
WO2006010568A2 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
IL180757A0 (en) Imidazo[4,5-d] pyrimidines, their uses and methods of preparation
IL186422A0 (en) Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
NZ593033A (en) 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine and 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine derivatives as PDE1 Inhibitors
HUP0402336A3 (en) Thieno[2,3-d]pyrimidine-2,4-dione derivatives, process for their preparation, their use in the modulation of autoimmune disease and pharmaceutical compositions containing them
IL207576A0 (en) Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-a]pyrimidines, methods for preparation and uses thereof
IL220174A (en) Acidic Salts of 5-Amino History- {Pyrazolo [3,4- e] –4,2,1- Triazolo [5,1– c] pyrimidine} preserved in positions 2 and 7 and pharmaceutical preparations coating them
WO2009151997A8 (en) Process for producing bicycloaniline derivatives
HUP0500332A3 (en) Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
IL201977A (en) 6- (Pyrrolidine-3-Yl) -Pyrazolo [4,3- d] Pyrimidine-4-Ones, Pharmaceuticals Including Them and Their Use in the Preparation of Medicines to Treat Diseases
BRPI0611095B8 (pt) compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostos
IL185913A0 (en) Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3h)-one derivatives
TNSN08143A1 (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-ones
HUP0402018A3 (en) 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0500328A3 (en) Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
WO2004094431A3 (en) 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
IL199651A (en) 8-cyclopropyl-3- [2- (3-fluorophenyl) ethyl] -8,7-dihydro-3 h- [3,1] oxazino [5,6- g] [3,2,1] benzotriazine -9,4 - Deion or pharmacist's salt of its acid or base, preparations that include it and its use
WO2007059500A3 (en) Novel process and formulations
IL197298A0 (en) Novel 5,7-disubstituted (1,3)thiazolo [4,5-d]pyrimidin-2 (3h)-amine derivatives and their use in therapy
WO2006010568A3 (de) Substituierte pyrido [3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1 h,3h)-diones und -4(3h)-one sowie pyrido [3',2' :4,5] furo[3,2-d]pyrimidin -2,4(1 h,3h)-dione und -4(3h)-one zur verwendung als inhibitoren der tnf-allpha freisetzung
IL197293A0 (en) Novel 5,7-disubstituted [1,3]thiazolo [4,5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy
WO2007010138A3 (fr) Derives de ν-(arylalkyl)-1h-pyrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
ZA200900165B (en) 4-amino-3-arylamino-6-arylpyrazolo[3,4-D]pyrimidine derivatives, methods for their preparation and their use as antiviral agents
UA98797C2 (en) 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro -1h-pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors
CA2483562A1 (en) Heterotricyclyl-6-alkylidene-penems as beta-lactamase inhibitors
PT2020410E (pt) Derivados de pirido[2,3-d]pirimidina, sua preparação, sua aplicação em terapêutica

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase